Adjuvant chemotherapy for bladder cancer

References

• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16(3), 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J. Urol. 165(4), 1111–1116 (2001).
   PubMed Web of Science ®Google Scholar
• Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J. Urol. 161(5), 1494–1497 (1999).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158(2), 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann. Oncol. 13(Suppl. 4), 273–279 (2002).
   PubMedGoogle Scholar
• Sternberg CN. Current perspectives in muscle invasive bladder cancer. Eur. J. Cancer 38(4), 460–467 (2002).
   PubMed Web of Science ®Google Scholar
• de Braud F, Maffezzini M, Vitale V et al. Bladder cancer. Crit. Rev. Oncol. Hematol. 41(1), 89–106 (2002).
   PubMedGoogle Scholar
• Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145, 459–467 (1991).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J. Urol. 148, 302–307 (1992).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153, 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Otto T, Börgemann C, Krege S et al. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1–2,M0) – a Phase III study. Eur. Urol. 39(Suppl. 5), 147 (2001).
   Google Scholar
• Studer UE, Bacchi M, Biedermann C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J. Urol. 152, 81–84 (1994).
   PubMed Web of Science ®Google Scholar
• Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155(2), 495–499 (1996).
   PubMed Web of Science ®Google Scholar
• Bono AV, Benvenuti C, Gibba A et al. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol. Ital. 11, 5–8 (1997).
   Google Scholar
• Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why. Ann. Oncol. 11(7), 851–856 (2000).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48(2), 189–201 (2005).
   PubMed Web of Science ®Google Scholar
• Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br. J. Urol. 62(6), 558–564 (1988).
   Google Scholar
• Richards B, Bastable JR, Freedman L et al. Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy. Br. J. Urol. 55(4), 386–391 (1983).
   Google Scholar
• Einstein AB Jr, Shipley W, Coombs J, Cummings KB, Soloway MS, Hawkins I. Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities. Urology 23(4 Suppl), 110–117 (1984).
   Google Scholar
• Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, Phase III trial (AUO-AB 05/95). J. Clin. Oncol. 23(22), 4963–4974 (2005).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Scher HI. Bladder cancer 'adjuvant-lite': tastes great (works as well) and less filling (less toxic)? J. Clin. Oncol. 23(22), 4823–4826 (2005).
   PubMedGoogle Scholar
• Sternberg CN, Yagoda A, Scher HI et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 64, 2448–2458 (1989).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PHM, Schornagel JH et al. Randomized Phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J. Clin. Oncol. 19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Albiol S, Tabernero JM, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit. Rev. Oncol. Hematol. 2, 195–206 (2003).
   Google Scholar
• Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder. N. Engl. J. Med. 331(19), 1259–1264 (1994).
   Google Scholar
• Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 385(6612), 123–125 (1997).
   Google Scholar
• Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J. Urol. 161(1), 20–22 (1999).
   Google Scholar